Company Startups

A key part of our mission is to move discoveries from the laboratory into the market.

One way we achieve this is through our faculty, who form startup companies based on their work. The following companies have been founded or co-founded by HSCI scientists:


Akouos | Founded 2017

HSCI Affiliate Faculty member Luk Vandenberghe, PhD is a co-founder of Akouos and currently serves as chair of the Scientific Advisory Board. The biotechnology company is developing gene therapies for hearing loss.


Alivio Therapeutics | Founded 2016

HSCI Principal Faculty member Jeffrey Karp, PhD is a co-founder and member of the Scientific Advisory Board of Alivio Therapeutics. Alivio is developing novel drug delivery technology for the treatment of inflammatory diseases.

Amasa Technologies logo image

Amasa Technologies | Founded 2015

HSCI Principal Faculty member Khalid Shah, PhD is the founder of Amasa Technologies, a private biotechnology company that focuses on the clinical translation of therapeutic stem cells in cancer patients.

Audion logo

Audion Therapeutics | Founded 2008

HSCI Affiliate Faculty member Albert Edge, PhD is a scientific co-founder of Audion Therapeutics, a private biopharmaceutical company dedicated to the discovery, development, and commercialization of drugs and delivery technologies for the treatment of diseases affecting the ear, including hearing loss.

CAMP4 logo image

CAMP4 Therapeutics | Founded 2016

CAMP4, founded by Executive Committee Chair Leonard Zon and the Whitehead's Richard Young, is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene production through signaling pathways the cell is already utilizing to regulate gene expression. Our predictions enable CAMP4 to have a rapid start to disease treatment, significantly reducing the time and risk to bring new medicines to patients.

Clear Creek Bio logo image

Clear Creek Bio | Founded 2017

Co-founded by HSCI Co-Director David Scadden, MD and Principal Faculty member David Sykes, MD, PhD, the enterprise develops therapies targeting molecular pathways in cancer cells that overcome differentiation blockade.


CRISPR Therapeutics | Founded 2013

HSCI Principal Faculty member Chad Cowan, PhD is a scientific co-founder of CRISPR Therapeutics, a biopharmaceutical company created to translate CRISPR-Cas9, a breakthrough genome-editing technology, into transformative medicines with the potential to cure human genetic diseases. 

Decibel logo

Decibel Therapeutics | Founded 2015

Decibel Therapeutics is translating scientific advances in inner ear biology, some of which originate from the laboratory of HSCI Affiliate Faculty member Albert Edge, PhD, into novel therapies for people with hearing loss and tinnitus.



Elevian | Founded 2017

Co-founded by HSCI Principal Faculty members Richard Lee, MD, Lee Rubin, PhD, and Amy Wagers, PhD, Elevian is developing regenerative medicines to target processes that are the root causes of aging.


enclear therapies logo

Enclear Therapies | Founded 2018

With co-founders Kevin Eggan, PhD, and Kasper Roet, PhD, EnClear's mission is to improve and extend the lives of genetically defined populations of patients suffering from neurodegenerative disease through the advancement of biomedical science and engineering to develop controlled access, delivery, and modification of cerebrospinal fluid

Epizyme logo

Epizyme | Founded 2007

HSCI Principal Faculty members George Daley MD, PhD and Yi Zhang, PhD are scientific co-founders of Epizyme, a startup company striving to redefine cancer therapy through targeted medicines for patients with unsolved diseases. It is currently conducting multiple clinical trials to understand the effects of the drug tazemetostat in patients with solid tumors.

Fate Therapeutics logo

Fate Therapeutics | Founded 2007

HSCI Co-Director David Scadden, MD and Executive Committee Chair Leonard Zon, MD are co-founders of Fate Therapeutics, a biopharmaceutical company focused on the discovery and development of adult stem cell modulators for patients with rare, life-threatening disorders—including certain hematologic malignancies, lysosomal storage disorders, and muscular dystrophies.

Frequency logo

Frequency Therapeutics | Founded 2015

Co-founded by HSCI Principal Faculty member Jeffrey Karp, PhD, Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue, including developing a small molecule that targets progenitor cells in the inner ear to treat noise-induced hearing loss.

Fulcrum Therapeutics

Fulcrum Therapeutics | Founded 2016
IPO issued July 18, 2019

The startup Fulcrum Therapeutics aims to develop medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Affiliate Faculty members Bradley Bernstein, MD, PhD and Jeannie Lee, MD, PhD are co-founders.

Gensight logo

GenSight Biologics | Founded 2011

HSCI Principal Faculty member Connie Cepko, PhD and Affiliate Faculty member Luk Vandenberghe, PhD are co-founders of the Paris-based GenSight Biologics. The biopharmaceutical company is dedicated to the development and commercialization of gene therapy-based treatments of retinal degenerative diseases.

Goldfinch Bio

Goldfinch Bio | Founded 2016

HSCI Executive Committee member Joseph Benventre, MD, PhD is a scientific co-founder of Goldfinch Bio, a company focused on discovering and developing precision therapies for patients with kidney disease.

Immunitas Therapeutics logo image

Immunitas Therapeutics | Founded 2019

With HSCI Principal Faculty member Mario Suva, MD, PhD and Affiliate Faculty member Kai Wucherpfennig, MD, PhD, both pioneers in the study of the immunobiology of human tumors, the company seeks to advance its first programs, monoclonal antibody therapeutics with single agent activity in preclinical models of oncology, to clinical studies.

Intellia logo

Intellia Therapeutics | Founded 2014

Intellia Therapeutics, co-founded by HSCI Principal Faculty member Derrick Rossi, PhD, is focused on developing and commercializing potentially curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases.

iPierian logo

iPierian | Founded 2007 | Acquired by Bristol-Myers Squibb 2014

HSCI Co-Director Douglas Melton, PhD, along with Principal Faculty members George Daley, MD, PhD and Lee Rubin, PhD, co-founded iPierian, which is developing therapies that inhibit the progression of Alzheimer's and other neurodegenerative diseases. 

IVIVA Medical

IVIVA Medical | Founded 2013

HSCI Principal Faculty member Harald Ott, MD is the founder and Chairman of the Board of IVIVA Medical, a company that is developing tissue-engineered treatments for end-state renal disease.

LifeVault Bio

LifeVault Bio | Founded 2017

HSCI Co-Director David Scadden, MD is a co-founder of LifeVault Bio, a company that collects and stores personalized biology — stem cells, DNA, and blood plasma — for future diagnostic and therapeutic purposes. Scadden currently serves as the Chairman of the Scientific Advisory Board.

Magenta logo

Magenta Therapeutics | Founded 2016

HSCI Co-Director David Scadden, MD and Principal Faculty member Derrick Rossi, PhD are scientific co-founders of Magenta Therapeutics, which is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients.

Moderna logo

Moderna Therapeutics | Founded 2010

HSCI Principal Faculty member Derrick Rossi, PhD translated a discovery in his laboratory into a whole new class of drugs now being developed by Moderna Therapeutics. The Cambridge-based company, which Rossi co-founded, uses messenger RNA to produce human proteins inside patient cells, which offers an innovative way to deliver drugs to a patient.

Nocion Therapeutics

Nocion Therapeutics | Founded 2019

HSCI Principal Faculty member Clifford Woolf, MB, BCh, PhD and colleague Bruce Bean, PhD, identified a novel class of sodium channel inhibitors that inhibits signaling in activated pain or itch neurons but spare all other neurons. This provides for targeted and sustained relief of conditions such as cough, itch, pain, and inflammation.

Odylia Therapeutics

Odylia Therapeutics | Founded 2018

HSCI Affiliate Faculty member Luk Vandenberghe, PhD is a co-founder and member of the Board of Directors of Odylia Therapeutics. The nonprofit organization accelerates clinical trials for gene therapies to treat rare eye diseases.

ProteoThera logo

ProteoThera, Inc. | Founded 2012

Co-founded by HSCI Principal Faculty member Richard Lee, MD, ProteoThera, Inc. is an early stage biotechnology company that is advancing drug targeting technology and is improving the clinical efficacy and safety of FDA-approved therapeutics to create a new paradigm in the treatment of autoinflammatory diseases and in tissue regeneration.

Q-State Biosciences logo

Q-State Biosciences | Founded 2014

Q-State Biosciences performs optical electrophysiology studies in human iPS-derived models of neuronal and cardiac diseases. The company combines the all-optical electrophysiology platform developed in the lab of HSCI Principal Faculty member Adam Cohen, PhD with the stem cell-based disease modeling expertise of Principal Faculty member Kevin Eggan, PhD to provide game-changing solutions to customers in pharma and academia, as well as to individual patients.

QurAlis logo image

QurAlis | Founded 2017

Founded by HSCI Faculty Kevin Eggan,  PhD, Kasper Roet, PhD, and Clifford Woolf, MD, PhD, the company is specifically focused on discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), the most common form of motor neuron disease.

Riparian Pharmaceuticals

Riparian Pharmaceuticals | Founded 2014

Riparian, co-founded by HSCI Affiliate Faculty member Guillermo Garcia-Cardena, PhD, is deploying hemodynamics as a tool to discover first-in-class therapeutics that act on new pathways at an earlier stage of disease than is possible today.

Sana logo

Sana Biotechnology | Founded 2019

Sana Biotechnology, co-founded by HSCI Principal Faculty member Chad Cowan, PhD, is focused on creating and delivering engineered cells as medicine for patients

Scholar Rock logo

Scholar Rock | Founded 2012

HSCI Executive Committee Chair Leonard Zon, MD is co-founder of Scholar Rock, which is developing a new class of biologic therapeutics, called niche activators, to target disease-causing proteins. The therapeutics, based on growth activator research by Zon and co-founder Timothy Springer, PhD of Harvard Medical School, have a wide range of disease applications including autoimmune diseases, fibrosis, and diseases of musculoskeletal systems.

Semma Therapeutics

Semma Therapeutics | Founded 2015

Utilizing and building on scientific breakthroughs from the laboratory of HSCI Co-Director Douglas Melton, PhD, Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections.

Sentien logo

Sentien Biotechnologies, Inc. | Founded 2008

HSCI Affiliate Faculty member Biju Parekkadan, PhD is a co-founder and director of Sentien Biotechnologies, which is developing new products that combine cell therapeutics with drug delivery systems to overcome the limitations of conventional cell administration.

TISSIUM logo image

Formerly Gecko Biomedical | Founded 2013
Rebranded May, 2019

HSCI Principal Faculty member Jeffrey Karp, PhD took a discovery from his lab to co-found Gecko Biomedical, a medical device company dedicated to the development and commercialization of novel biodegradable bio-inspired adhesives in the field of surgery, with a key focus on minimally invasive surgery. Karp is now chairman of the company's clinical and scientific advisory boards.

28-7 logo image

Twentyeight-Seven Therapeutics | Founded 2016

Twentyeight-Seven Therapeutics was founded by HSCI Principal Faculty members George Daley, MD, Richard Gregory, PhD, and Frank Slack, PhD, along with Affiliate Faculty member Piotr Sliz, PhD. The company is developing small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs.

Yumanity Therapeutics logo

Yumanity Therapeutics | Founded 2014

HSCI Principal Faculty member Vikram Khurana, MD, PhD is a scientific co-founder of Yumanity Therapeutics, a company based in Cambridge, Massachusetts that aims to develop drugs for neurodegenerative diseases such as Alzheimer's, Parkinson's and Lou Gehrig's. A key component of Yumanity's discovery platform is the use of patient-derived stem cells for modeling the protein-misfolding pathologies that characterize these diseases.